What SEC filings does Zomedica Corp. submit to the SEC?

Zomedica Corp. (ZOMDF) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ZOMDF?

A Form 4 for ZOMDF discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Zomedica Corp.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ZOMDF?

The 10-K is Zomedica Corp.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ZOMDF SEC filings directly on EDGAR?

You can view all historical Zomedica Corp. filings on the SEC EDGAR company page for ZOMDF. Each filing card on this page links directly to the original SEC document.

How often does Zomedica Corp. file with the SEC?

Zomedica Corp. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ZOMDF shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ZOMDF SEC Filing News — Zomedica Corp.

Latest SEC filings for Zomedica Corp. (ZOMDF) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-07.

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic sho…

Sector: Healthcare Industry: Medical Devices Market Cap: $77.4M CIK: 1684144

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ZOMDF currently lean bullish. Of the 20 displayed SEC filing records, 6 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 13 insider transactions (Form 4) in this period.

ZOMDF Filing Activity Snapshot 2025-11-18 — 2026-08-07

Insider Transactions (Form 4)

6 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$56.4K

POWERS JOHNNY D (Director) · 2026-05-11

500,000 shares · Form 4

Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Zomedica Corp.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 7 compensation award and 6 open-market purchase. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×6: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-08-07

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

Blair Anthony K (COO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Options to buy Common Stock	500,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Blair Anthony K (COO)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-07

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

DeHaan-Fullerton Karen (General Counsel) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Options to buy Common Stock	250,000	—	—

Filing: Form 4 (Insider Transaction) Insider: DeHaan-Fullerton Karen (General Counsel)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-07

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

Klass Russell Kevin (Sr Vice President, Sales) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Options to buy Common Stock	250,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Klass Russell Kevin (Sr Vice President, Sales)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-26

ZOMDF insider Klass Russell Kevin (Sr. Vice President, Sales) bought 104,000 shares (~$10.7K)

Klass Russell Kevin, listed as Sr. Vice President, Sales at Zomedica Corp., reported an open-market purchase of 104,000 ZOMDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	104,000	$0.10	$10.7K

Filing: Form 4 (Insider Transaction) Insider: Klass Russell Kevin (Sr. Vice President, Sales) Shares: 104,000 Est. Value: $10.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-21

ZOMDF insider POWERS JOHNNY D (Director) bought 200,000 shares (~$20.6K)

POWERS JOHNNY D, listed as Director at Zomedica Corp., reported an open-market purchase of 200,000 ZOMDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$0.10	$10.3K
`P`	Open-market purchase	2,485	$0.10	$255.95
`P`	Open-market purchase	97,515	$0.10	$10.0K

Filing: Form 4 (Insider Transaction) Insider: POWERS JOHNNY D (Director) Shares: 200,000 Est. Value: $20.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-21

ZOMDF insider Klass Russell Kevin (Insider) bought 216,899 shares (~$22.8K)

Klass Russell Kevin, listed as Insider at Zomedica Corp., reported an open-market purchase of 216,899 ZOMDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	200,000	$0.10	$21.0K
`P`	Open-market purchase	11,399	$0.11	$1.2K
`P`	Open-market purchase	5,500	$0.10	$577.50

Filing: Form 4 (Insider Transaction) Insider: Klass Russell Kevin (Insider) Shares: 216,899 Est. Value: $22.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-14

ZOMDF insider POWERS JOHNNY D (Director) bought 300,000 shares (~$31.7K)

POWERS JOHNNY D, listed as Director at Zomedica Corp., reported an open-market purchase of 300,000 ZOMDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$0.10	$10.5K
`P`	Open-market purchase	200,000	$0.11	$21.2K

Filing: Form 4 (Insider Transaction) Insider: POWERS JOHNNY D (Director) Shares: 300,000 Est. Value: $31.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-11

ZOMDF insider POWERS JOHNNY D (Director) bought 500,000 shares (~$56.4K)

POWERS JOHNNY D, listed as Director at Zomedica Corp., reported an open-market purchase of 500,000 ZOMDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	108,871	$0.11	$12.2K
`P`	Open-market purchase	391,129	$0.11	$44.2K

Filing: Form 4 (Insider Transaction) Insider: POWERS JOHNNY D (Director) Shares: 500,000 Est. Value: $56.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-08

ZOMDF insider HEATON LARRY C II (Director, CEO) bought 250,000 shares (~$27.5K)

HEATON LARRY C II, listed as Director, CEO at Zomedica Corp., reported an open-market purchase of 250,000 ZOMDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	250,000	$0.11	$27.5K

Filing: Form 4 (Insider Transaction) Insider: HEATON LARRY C II (Director, CEO) Shares: 250,000 Est. Value: $27.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-11-18

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

Whelan Sean (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Appreciation Right	1,975,033	—	—

Filing: Form 4 (Insider Transaction) Insider: Whelan Sean (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-11-18

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

POWERS JOHNNY D (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Appreciation Right	1,823,107	—	—

Filing: Form 4 (Insider Transaction) Insider: POWERS JOHNNY D (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-11-18

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

Nichols Pamela (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Appreciation Right	1,823,107	—	—

Filing: Form 4 (Insider Transaction) Insider: Nichols Pamela (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-11-18

ZOMDF insider Form 4 filed for equity award, exercise, or tax withholding

MACLEOD CHRISTOPHER ROSS (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Appreciation Right	1,823,107	—	—

Filing: Form 4 (Insider Transaction) Insider: MACLEOD CHRISTOPHER ROSS (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Zomedica Corp. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

ZOMDF filed 8-K — material company event

Zomedica Corp. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-11

ZOMDF filed 8-K — material company event

Zomedica Corp. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-06

ZOMDF filed 8-K — material company event

Zomedica Corp. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-03-16

ZOMDF filed 8-K — material company event

Zomedica Corp. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Zomedica Corp.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

ZOMDF filed Quarterly Report (10-Q)

Zomedica Corp. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-06

ZOMDF filed Quarterly Report (10-Q)

Zomedica Corp. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-03-16

ZOMDF filed Annual Report (10-K)

Zomedica Corp. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify Zomedica Corp.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ZOMDF. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ZOMDF SEC Filings

More Tools for ZOMDF

ZOMDF Full Stock Analysis ZOMDF Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ZOMDF analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ZOMDF stock analysis page.

ZOMDF Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer